Bank of Montreal Can boosted its position in Exelixis, Inc. (NASDAQ:EXEL) by 21.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 116,024 shares of the biotechnology company’s stock after buying an additional 20,824 shares during the period. Bank of Montreal Can owned about 0.05% of Exelixis worth $1,483,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in EXEL. Amalgamated Bank increased its stake in Exelixis by 2.5% in the second quarter. Amalgamated Bank now owns 24,322 shares of the biotechnology company’s stock worth $259,000 after buying an additional 591 shares during the last quarter. Fox Run Management L.L.C. increased its stake in Exelixis by 12.5% in the third quarter. Fox Run Management L.L.C. now owns 11,700 shares of the biotechnology company’s stock worth $150,000 after buying an additional 1,300 shares during the last quarter. ProShare Advisors LLC increased its stake in Exelixis by 0.8% in the second quarter. ProShare Advisors LLC now owns 198,085 shares of the biotechnology company’s stock worth $1,547,000 after buying an additional 1,588 shares during the last quarter. Prudential Financial Inc. increased its stake in Exelixis by 11.3% in the second quarter. Prudential Financial Inc. now owns 19,643 shares of the biotechnology company’s stock worth $153,000 after buying an additional 2,000 shares during the last quarter. Finally, Teacher Retirement System of Texas increased its stake in Exelixis by 12.3% in the second quarter. Teacher Retirement System of Texas now owns 31,452 shares of the biotechnology company’s stock worth $246,000 after buying an additional 3,448 shares during the last quarter. Institutional investors own 75.97% of the company’s stock.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Shares of Exelixis, Inc. (NASDAQ:EXEL) traded down 1.65% during midday trading on Friday, hitting $18.51. The company’s stock had a trading volume of 5,339,429 shares. The company has a 50-day moving average price of $16.29 and a 200 day moving average price of $12.40. The company’s market cap is $5.30 billion. Exelixis, Inc. has a 1-year low of $3.55 and a 1-year high of $19.30.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Thursday, November 3rd. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.09. The firm had revenue of $62.19 million for the quarter, compared to analyst estimates of $43.15 million. During the same period last year, the business earned ($0.22) EPS. The company’s revenue was up 531.1% compared to the same quarter last year. On average, equities research analysts predict that Exelixis, Inc. will post ($0.45) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Bank of Montreal Can Purchases 20,824 Shares of Exelixis, Inc. (EXEL)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be viewed at http://www.dailypolitical.com/2017/01/13/bank-of-montreal-can-purchases-20824-shares-of-exelixis-inc-exel.html.

A number of equities research analysts recently commented on the company. Cowen and Company reiterated an “outperform” rating on shares of Exelixis in a report on Wednesday, October 12th. William Blair reiterated an “outperform” rating on shares of Exelixis in a report on Thursday, September 15th. Zacks Investment Research downgraded Exelixis from a “buy” rating to a “hold” rating in a report on Tuesday, January 3rd. Deutsche Bank AG assumed coverage on Exelixis in a report on Thursday, November 3rd. They issued a “buy” rating and a $17.00 price objective for the company. Finally, Leerink Swann reiterated an “outperform” rating and issued a $12.00 price objective on shares of Exelixis in a report on Tuesday, September 20th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $14.93.

In other Exelixis news, Director Alan M. Garber sold 7,832 shares of Exelixis stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $16.90, for a total transaction of $132,360.80. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director George A. Scangos sold 204,894 shares of Exelixis stock in a transaction dated Wednesday, December 7th. The stock was sold at an average price of $17.81, for a total value of $3,649,162.14. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. It focuses on the development and commercialization of cabozantinib, an inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is indicated for the treatment of progressive, metastatic medullary thyroid cancer, and is sold under the brand name COMETRIQ.

5 Day Chart for NASDAQ:EXEL

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.